Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.

de Leeuw, David C; Ossenkoppele, Gert J; Janssen, Jeroen J W M

de Leeuw, David C; Ossenkoppele, Gert J; Janssen, Jeroen J W M.

Affiliation

de Leeuw DC; Department of Hematology, Amsterdam University Medical Centers, Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. d.deleeuw@amsterdamumc.nl.
Ossenkoppele GJ; Department of Hematology, Amsterdam University Medical Centers, Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Janssen JJWM; Department of Hematology, Amsterdam University Medical Centers, Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Curr Oncol Rep ; 24(11): 1387-1400, 2022 11.

Article in En | MEDLINE | ID: mdl-35653050

Subject(s)

Leukemia, Myeloid, Acute; Humans; Aged; Leukemia, Myeloid, Acute/drug therapy; Protein Kinase Inhibitors/therapeutic use; Azacitidine/therapeutic use

Key words

Acute myeloid leukemia; Azacitidine; CC-486; CPX-351; Decitabine; Elderly; Enasidenib; FTL3 inhibitors; Fitness; Gemutuzumab ozogamicin; Gilteritinib; Glasdegib; Hematopoietic stem cell transplantation; Hypomethylating agents; IDH inhibitors; Intensive chemotherapy; Ivosidenib; Midostaurin; Targeted therapy; Treatment; Venetoclax; Vyxeos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute Type of study: Guideline Limits: Aged / Humans Language: En Journal: Curr Oncol Rep Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Netherlands Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google